儿科状态的洛拉泽帕姆与迪亚泽帕姆:一个随机临床试验
James M Chamberlain1, Pamela Okada2, Maija Holsti3
1Division of Emergency Medicine, Children's National Medical Center, Washington, DC2The Pediatric Emergency Care Applied Research Network (PECARN).
JAMA
|April 24, 2014
概括
在一项随机试验中,洛拉泽巴姆在治疗儿科病情的治疗中没有比迪亚泽巴姆提高疗效或安全性. 这些发现不支持在这种情况下优先使用洛拉泽帕姆.
科学领域:
- 儿科急救医学 儿科急救医学
- 临床药理学 临床药理学
- 神经学 神经学
背景情况:
- 二是治疗儿科状态的第一线治疗方法.
- 洛拉泽帕姆被认为比迪亚泽帕姆更有效或更安全,但未经FDA批准.
研究的目的:
- 为了比较lorazepam与diazepam在治疗儿科状态的疗效和安全性.
主要方法:
- 一个双盲,随机的临床试验,涉及273名儿科患者,患有性状态.
- 患者接受了静脉注射的迪亚泽帕姆 (0.2毫克/千克) 或洛拉泽帕姆 (0.1毫克/千克),可选择重复剂量.
- 主要结局包括停止和需要辅助通风.
主要成果:
- 两组之间的疗效差不多:对diazepam的72.1%和对lorazepam的72.9%.
- 辅助通风率也相当于:16.0%的迪亚泽巴姆,而17.6%的洛拉泽巴姆.
- 洛拉泽巴姆与镇静的增加有关 (66.9%与50%).
结论:
- 洛拉泽没有在治疗儿科病情症方面表现出高于泽的疗效或安全性.
- 目前的研究结果不支持在这种情况下优先使用洛拉泽帕姆.
- 进一步的研究可能会探索为儿科状态的最佳二胺选择.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Excretion
408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Drug Dosing: Infants and Children
1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Distribution
554
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Anxiolytic Drugs: Benzodiazepines and Buspirone
3.1K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
3.1K
Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967


